Liquidia Corporation Set to Showcase Innovations at Conference
Morrisville, N.C. — Liquidia Corporation (NASDAQ: LQDA), a pioneering biopharmaceutical company, is gearing up to present at the 24th Annual Needham Virtual Healthcare Conference. This presentation promises to highlight Liquidia's vision and advancements in treating rare cardiopulmonary diseases. During this insightful session, the company will conduct a fireside chat on Tuesday, providing an in-depth overview of its business strategy and innovative therapies.
The presentation is slated to begin at 8:45 a.m. ET, and attendees will have the option to access a live webcast through the company's official website. Liquidia is dedicated to transparency with its investors, and a recorded version will be accessible for at least 30 days post-event. This approach reflects its commitment to keeping stakeholders informed of the latest developments.
About Liquidia Corporation
Innovative Therapies for Unique Challenges
Liquidia Corporation specializes in developing cutting-edge therapies aimed at addressing the needs of patients suffering from rare cardiopulmonary diseases. At the heart of their mission is the commitment to improving patient outcomes through groundbreaking medical solutions. The company utilizes its proprietary PRINT Technology to create innovative treatments, including the lead candidate, YUTREPIA™ (treprostinil) inhalation powder. This investigational drug targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), providing new hope for affected individuals.
Product Pipeline and Future Goals
In addition to YUTREPIA™, Liquidia is developing other promising products like L606, an investigational sustained-release formulation of treprostinil. This formulation is designed for twice-daily administration using advanced nebulizer technology, which aims to enhance the convenience and effectiveness of treatment for patients. Furthermore, the company also markets generic Treprostinil Injection for the treatment of PAH, underscoring its commitment to accessibility in medication.
Commitment to Transparency and Communication
Liquidia Corporation places substantial emphasis on maintaining open channels of communication with its investors and the media. With a dedicated Investor Relations team, the company strives to provide relevant information and respond to inquiries promptly. Investors can reach out directly to the Chief Business Officer, Jason Adair, for insights into the company’s direction and strategy. Additionally, for media-related inquiries, Patrick Wallace, the Director of Corporate Communications, is available to address questions and share the latest news about Liquidia's developments.
This proactive approach not only aids in building trust and confidence among stakeholders but also positions Liquidia as a frontrunner in the biopharmaceutical landscape.
Frequently Asked Questions
What is Liquidia Corporation focused on?
Liquidia Corporation focuses on developing innovative therapies for patients with rare cardiopulmonary diseases through its proprietary PRINT Technology.
When is Liquidia's presentation at the Needham Virtual Healthcare Conference?
The presentation is scheduled for Tuesday, starting at 8:45 a.m. ET.
Where can I watch Liquidia's presentation?
Access the presentation through the “Investors” page on Liquidia’s official website.
What are Liquidia's key product candidates?
Key product candidates include YUTREPIA™ for PAH and L606, an investigational sustained-release formulation of treprostinil.
Who can I contact for more information regarding Liquidia?
For inquiries, you can contact Jason Adair for investor relations or Patrick Wallace for media inquiries.
